ResMed Inc. (NYSE:RMD) is looking for tuck-in acquisitions. Brett Sandercock, Chief Financial Officer said, "Going forward, we plan to continue to reinvest in growth through R&D and also expect to continue to deploy capital for tuck-in acquisitions, such as the recently announced acquisition of mementor, a German pioneer and health tech start-up that develops and distributes digital medical products in the field of sleep medicine and related areas".
Market Closed -
Other stock markets
|
Pre-market 09:20:08 am | |||
183.4 USD | -0.20% | 204.1 | +11.26% |
03:09pm | Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating | MT |
03:00pm | JPMorgan Adjusts Price Target on ResMed to $225 From $198 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.63% | 26.94B | |
+7.71% | 218B | |
+6.25% | 182B | |
+10.60% | 132B | |
+26.73% | 108B | |
+15.42% | 52.98B | |
-1.89% | 47.59B | |
-1.91% | 39.96B | |
+11.16% | 39.22B | |
-13.06% | 19.28B |
- Stock Market
- Equities
- RMD Stock
- News ResMed, Inc.
- ResMed Seeks Tuck-In Acquisitions